KPV
Lys-Pro-Val · α-MSH(11-13)
Anti-inflammatory tripeptide from α-MSH, active in mouse colitis models; no human trials.
Not FDA-approved. Research only. FDA Category 2 bulk listing. This page describes research and public discussion; it is not a recommendation to use.
Overview
KPV is the C-terminal fragment of alpha-melanocyte-stimulating hormone. Oral nanoparticle formulations reduced colitis in mice.
Mechanism of action
Enters cells via PepT1 transporter and inhibits NF-κB inflammatory signaling.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Clinically studied C Preliminary research | None | — | — | — |
Online protocols D Anecdotal / community | 200–500 mcg | Daily | 4–8 weeks | Oral / subcutaneous |
Clinical trials & studies
- Animal2008PepT1-mediated KPV uptake reduces intestinal inflammation (Gastroenterology)
Mouse colitis models.
Safety
Side effects
- Unknown
Contraindications
- Pregnancy
Interactions
- Unknown
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Research only. FDA Category 2 bulk listing.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.